Metod Oblak

2.6k total citations
3 papers, 33 citations indexed

About

Metod Oblak is a scholar working on Oncology, Public Health, Environmental and Occupational Health and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Metod Oblak has authored 3 papers receiving a total of 33 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Oncology, 3 papers in Public Health, Environmental and Occupational Health and 2 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Metod Oblak's work include Cancer survivorship and care (3 papers), Palliative Care and End-of-Life Issues (3 papers) and Childhood Cancer Survivors' Quality of Life (2 papers). Metod Oblak is often cited by papers focused on Cancer survivorship and care (3 papers), Palliative Care and End-of-Life Issues (3 papers) and Childhood Cancer Survivors' Quality of Life (2 papers). Metod Oblak collaborates with scholars based in United Kingdom and Italy. Metod Oblak's co-authors include Μαρίνα Καρακάντζα, Graham P. Collins, Esther N. Oliva, Tatyana Ionova, Magda Al-Obaidi, Sam Salek, Saad Al‐Ismail, Stewart McConnell, Adele K. Fielding and Jonathan Kell and has published in prestigious journals such as Frontiers in Pharmacology and Journal of Comparative Effectiveness Research.

In The Last Decade

Metod Oblak

3 papers receiving 33 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Metod Oblak United Kingdom 3 18 14 13 13 6 3 33
Magda Al-Obaidi United Kingdom 4 18 1.0× 14 1.0× 13 1.0× 14 1.1× 6 1.0× 4 36
Ludmila de Oliveira Muniz Koch Brazil 4 10 0.6× 15 1.1× 6 0.5× 12 0.9× 4 0.7× 6 35
Ashok Kalwar India 5 18 1.0× 13 0.9× 10 0.8× 13 1.0× 5 0.8× 10 45
Robert Mbuli Lukamba Democratic Republic of the Congo 5 12 0.7× 10 0.7× 13 1.0× 8 0.6× 3 0.5× 5 45
Arlene A. Gayle United States 4 16 0.9× 8 0.6× 6 0.5× 8 0.6× 4 0.7× 8 39
D.-M. Zahm Germany 4 12 0.7× 13 0.9× 14 1.1× 4 0.3× 9 1.5× 4 35
Martha Margarita Velázquez‐Aviña Mexico 3 10 0.6× 7 0.5× 9 0.7× 10 0.8× 5 0.8× 5 32
Hoong‐Yin Chong Malaysia 4 13 0.7× 5 0.4× 15 1.2× 4 0.3× 4 0.7× 5 42
Hacène Zerazhi France 4 12 0.7× 18 1.3× 7 0.5× 16 1.2× 1 0.2× 7 35
C. Pittman United States 2 10 0.6× 12 0.9× 15 1.2× 7 0.5× 2 0.3× 2 36

Countries citing papers authored by Metod Oblak

Since Specialization
Citations

This map shows the geographic impact of Metod Oblak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Metod Oblak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Metod Oblak more than expected).

Fields of papers citing papers by Metod Oblak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Metod Oblak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Metod Oblak. The network helps show where Metod Oblak may publish in the future.

Co-authorship network of co-authors of Metod Oblak

This figure shows the co-authorship network connecting the top 25 collaborators of Metod Oblak. A scholar is included among the top collaborators of Metod Oblak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Metod Oblak. Metod Oblak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

3 of 3 papers shown
1.
Oliva, Esther N., Tatyana Ionova, Jonathan Kell, et al.. (2020). Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study. Frontiers in Pharmacology. 11. 1308–1308. 12 indexed citations
2.
Oliva, Esther N., Tatyana Ionova, Jonathan Kell, et al.. (2020). Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO. Frontiers in Pharmacology. 11. 571066–571066. 5 indexed citations
3.
Oliva, Esther N., Tatyana Ionova, Jonathan Kell, et al.. (2019). Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence study. Journal of Comparative Effectiveness Research. 8(7). 523–533. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Magda Al-Obaidi Breakdown of academic impact, for papers by Ludmila de Oliveira Muniz Koch Breakdown of academic impact, for papers by Ashok Kalwar Breakdown of academic impact, for papers by Robert Mbuli Lukamba Breakdown of academic impact, for papers by Arlene A. Gayle Breakdown of academic impact, for papers by D.-M. Zahm Breakdown of academic impact, for papers by Martha Margarita Velázquez‐Aviña Breakdown of academic impact, for papers by Hoong‐Yin Chong Breakdown of academic impact, for papers by Hacène Zerazhi Breakdown of academic impact, for papers by C. Pittman
Rankless by CCL
2026